Lowered Risk Leads to Long-term Gains
TFF Pharmaceuticals (TFFP) is a small biotech company that focuses on a novel small molecule/biosimilar aerosolization technique. I find this company to be a necessary asset in a biotech portfolio as it provides an ingenious manufacturing procedure that leads to a lower risk scenario. As initial data has indicated, the safety and efficacy of the technology is positive as of an initial phase I trial. Correspondingly, the range and diversity of potential therapies is an important factor for future growth because the company is looking to license